KUALA LUMPUR, April 8 (Bernama) -- Meiji Seika Pharma Co Ltd has announced that its subsidiary, Meiji Pharma Asia Pte Ltd, commenced operations in Singapore on April 1, marking a strategic move to strengthen its presence in the ASEAN region.
In a statement, the company said the Singapore-based subsidiary will support the commercialisation, marketing and distribution of pharmaceuticals, including vaccines, across the region.
Meiji Seika Pharma aims to become “a leading company in Asia in the field of infectious diseases” under its “Meiji Group 2026 Vision”, leveraging nearly half a century of experience in manufacturing and marketing pharmaceuticals in Thailand and Indonesia.
Singapore will serve as a regional hub for the company’s business and commercial strategies, aimed at enhancing its influence and accelerating growth across ASEAN markets.
Established on Dec 10, 2025, Meiji Pharma Asia will focus on pharmaceuticals for infectious diseases, haematologic cancers and lifestyle-related diseases, with the aim of ensuring reliable supply and contributing to public health in the region.
-- BERNAMA
